A Review of Prostate Organogenesis and a Role for IPSC-Derived Prostate Organoids to Study Prostate Development and Disease
Overview
Chemistry
Molecular Biology
Affiliations
The prostate is vulnerable to two major age-associated diseases, cancer and benign enlargement, which account for significant morbidity and mortality for men across the globe. Prostate cancer is the most common cancer reported in men, with over 1.2 million new cases diagnosed and 350,000 deaths recorded annually worldwide. Benign prostatic hyperplasia (BPH), characterised by the continuous enlargement of the adult prostate, symptomatically afflicts around 50% of men worldwide. A better understanding of the biological processes underpinning these diseases is needed to generate new treatment approaches. Developmental studies of the prostate have shed some light on the processes essential for prostate organogenesis, with many of these up- or downregulated genes expressions also observed in prostate cancer and/or BPH progression. These insights into human disease have been inferred through comparative biological studies relying primarily on rodent models. However, directly observing mechanisms of human prostate development has been more challenging due to limitations in accessing human foetal material. Induced pluripotent stem cells (iPSCs) could provide a suitable alternative as they can mimic embryonic cells, and iPSC-derived prostate organoids present a significant opportunity to study early human prostate developmental processes. In this review, we discuss the current understanding of prostate development and its relevance to prostate-associated diseases. Additionally, we detail the potential of iPSC-derived prostate organoids for studying human prostate development and disease.
Shams S, Dawud D, Michalak K, Makhlouf M, Moustafa A, Jazwinski S Am J Cancer Res. 2025; 14(12):5697-5716.
PMID: 39803655 PMC: 11711525. DOI: 10.62347/XXXA3182.
Wang S, Yu Y, Li Y, Zhang T, Jiang W, Wang X Stem Cell Res Ther. 2024; 15(1):274.
PMID: 39218930 PMC: 11367998. DOI: 10.1186/s13287-024-03886-y.
Wang X, He W, Chen H, Yang R, Su H, DiSanto M J Pers Med. 2024; 14(4).
PMID: 38673008 PMC: 11051519. DOI: 10.3390/jpm14040381.
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.
Chehelgerdi M, Dehkordi F, Chehelgerdi M, Kabiri H, Salehian-Dehkordi H, Abdolvand M Mol Cancer. 2023; 22(1):189.
PMID: 38017433 PMC: 10683363. DOI: 10.1186/s12943-023-01873-0.
Singh P, Lanman N, Kendall H, Wilson L, Long R, Franco O Development. 2023; 150(13).
PMID: 37376888 PMC: 10357030. DOI: 10.1242/dev.201328.